User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

Primary tabs

Cornelissen, J J Versluis, J Passweg, J R van Putten, W L J Manz, M G Vekemans, Marie-Christiane [UCL] Graux, Carlos [UCL] Löwenberg, B

The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) (n=337) versus chemotherapy (n=271) or autologous HSCT (autoHSCT) (n=152) in 760 patients aged 40-60 years with AML in CR1. Patients receiving alloHSCT showed improved overall survival (OS) as compared with chemotherapy (respectively, 57±3% vs 40±3% at 5 years, P<0.001). Comparable OS was observed following alloHSCT and autoHSCT in patients with intermediate-risk AML (60±4 vs 54±5%). However, alloHSCT was associated with less relapse (hazard ratio (HR) 0.51, P<0.001) and better relapse-free survival (RFS) (HR 0.74, P=0.029) as compared with autoHSCT in intermediate-risk AMLs. AlloHSCT was applied following myeloablative conditioning (n=157) or reduced intensity conditioning (n=180), resulting in less NRM, but comparable outcome with respect to OS, RFS and relapse. Collectively, these results show that alloHSCT is to be preferred over chemotherapy as PRT in patients with intermediate- and poor-risk AML aged 40-60 years, whereas autoHSCT remains a treatment option to be considered in patients with intermediate-risk AML.Leukemia advance online publication, 23 December 2014; doi:10.1038/leu.2014.332.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2015
Language Anglais
Journal information "Leukemia" - Vol. 29, no. 5, p. 1041-1050 (2015)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 0887-6924
e-issn 1476-5551
Publication status Publié
Affiliations UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'hématologie
UCL - (SLuc) Service d'hématologie
Links
  1. Dohner H., Estey E. H., Amadori S., Appelbaum F. R., Buchner T., Burnett A. K., Dombret H., Fenaux P., Grimwade D., Larson R. A., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G. J., Sanz M. A., Sierra J., Tallman M. S., Lowenberg B., Bloomfield C. D., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, 10.1182/blood-2009-07-235358
  2. Burnett Alan, Wetzler Meir, Löwenberg Bob, Therapeutic Advances in Acute Myeloid Leukemia, 10.1200/jco.2010.30.1820
  3. Patel Jay P., Gönen Mithat, Figueroa Maria E., Fernandez Hugo, Sun Zhuoxin, Racevskis Janis, Van Vlierberghe Pieter, Dolgalev Igor, Thomas Sabrena, Aminova Olga, Huberman Kety, Cheng Janice, Viale Agnes, Socci Nicholas D., Heguy Adriana, Cherry Athena, Vance Gail, Higgins Rodney R., Ketterling Rhett P., Gallagher Robert E., Litzow Mark, van den Brink Marcel R.M., Lazarus Hillard M., Rowe Jacob M., Luger Selina, Ferrando Adolfo, Paietta Elisabeth, Tallman Martin S., Melnick Ari, Abdel-Wahab Omar, Levine Ross L., Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia, 10.1056/nejmoa1112304
  4. Ferrara Felicetto, Schiffer Charles A, Acute myeloid leukaemia in adults, 10.1016/s0140-6736(12)61727-9
  5. Sanders Mathijs A., Valk Peter J.M., The evolving molecular genetic landscape in acute myeloid leukaemia : , 10.1097/moh.0b013e32835d821c
  6. Koreth John, Schlenk Richard, Kopecky Kenneth J., Honda Sumihisa, Sierra Jorge, Djulbegovic Benjamin J., Wadleigh Martha, DeAngelo Daniel J., Stone Richard M., Sakamaki Hisashi, Appelbaum Frederick R., Döhner Hartmut, Antin Joseph H., Soiffer Robert J., Cutler Corey, Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission : Systematic Review and Meta-analysis of Prospective Clinical Trials, 10.1001/jama.2009.813
  7. Burnett Alan K., Goldstone Anthony, Hills Robert K., Milligan Donald, Prentice Archie, Yin John, Wheatley Keith, Hunter Ann, Russell Nigel, Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission, 10.1200/jco.2011.40.5977
  8. Pfirrmann Markus, Ehninger Gerhard, Thiede Christian, Bornhäuser Martin, Kramer Michael, Röllig Christoph, Hasford Joerg, Schaich Markus, Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial, 10.1016/s1470-2045(11)70326-6
  9. Forman S. J., Rowe J. M., The myth of the second remission of acute leukemia in the adult, 10.1182/blood-2012-08-234492
  10. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J, Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation, 10.1016/s0140-6736(98)03030-x
  11. Sorror M. L., Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, 10.1182/blood-2005-05-2004
  12. Cornelissen Jan J., Gratwohl Alois, Schlenk Richard F., Sierra Jorge, Bornhäuser Martin, Juliusson Gunnar, Råcil Zdenek, Rowe Jacob M., Russell Nigel, Mohty Mohamad, Löwenberg Bob, Socié Gerard, Niederwieser Dietger, Ossenkoppele Gert J., The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach, 10.1038/nrclinonc.2012.150
  13. Cornelissen J. J., van Putten W. L. J., Verdonck L. F., Theobald M., Jacky E., Daenen S. M. G., van Marwijk Kooy M., Wijermans P., Schouten H., Huijgens P. C., van der Lelie H., Fey M., Ferrant A., Maertens J., Gratwohl A., Lowenberg B., Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?, 10.1182/blood-2006-06-025627
  14. Burnett AK, Clin Adv Hematol Oncol, 4, 445 (2006)
  15. Suciu S., Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial, 10.1182/blood-2002-12-3714
  16. Jourdan Eric, Boiron Jean-Michel, Dastugue Nicole, Vey Norbert, Marit Gérald, Rigal-Huguet Françoise, Molina Lysiane, Fegueux Nathalie, Pigneux Arnaud, Recher Christian, Rossi Jean-François, Attal Michel, Sotto Jean-Jacques, Maraninchi Dominique, Reiffers Josy, Bardou Valerie-Jeanne, Esterni Benjamin, Blaise Didier, Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience, 10.1200/jco.2005.02.5940
  17. McSweeney P. A., Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects, 10.1182/blood.v97.11.3390
  18. Hegenbart Ute, Niederwieser Dietger, Sandmaier Brenda M., Maris Michael B., Shizuru Judith A., Greinix Hildegard, Cordonnier Catherine, Rio Bernard, Gratwohl Alois, Lange Thoralf, Al-Ali Haifa, Storer Barry, Maloney David, McSweeney Peter, Chauncey Thomas, Agura Ed, Bruno Benedetto, Maziarz Richard T., Petersen Finn, Storb Rainer, Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors, 10.1200/jco.2005.03.1765
  19. Vellenga E., van Putten W., Ossenkoppele G. J., Verdonck L. F., Theobald M., Cornelissen J. J., Huijgens P. C., Maertens J., Gratwohl A., Schaafsma R., Schanz U., Graux C., Schouten H. C., Ferrant A., Bargetzi M., Fey M. F., Lowenberg B., , Autologous peripheral blood stem cell transplantation for acute myeloid leukemia, 10.1182/blood-2011-07-370247
  20. Herr A-L, Labopin M, Blaise D, Milpied N, Potter M, Michallet M, Heit W, Ferrara F, Esteve J, Arcese W, Ehninger G, Rowe J M, Kobbe G, Rosselet A, Bunjes D, Rio B, Brune M, Nagler A, Gorin N C, Frassoni F, Rocha V, HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia, 10.1038/sj.leu.2404461
  21. Keating A., DaSilva G., Perez W. S., Gupta V., Cutler C. S., Ballen K. K., Cairo M. S., Camitta B. M., Champlin R. E., Gajewski J. L., Lazarus H. M., Lill M., Marks D. I., Nabhan C., Schiller G. J., Socie G., Szer J., Tallman M. S., Weisdorf D. J., Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research, 10.3324/haematol.2012.062059
  22. Ferrara Felicetto, Renaissance of autologous stem cell transplantation for AML?, 10.1016/s1470-2045(11)70395-3
  23. Hospital M A, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis J-H, Reman O, de Revel T, Terré C, Preudhomme C, Fenaux P, Michallet M, Socié G, Dombret H, Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML, 10.1038/bmt.2012.49
  24. Cornelissen Jan J., Breems Dimitri, van Putten Wim L.J., Gratwohl Alois A., Passweg Jakob R., Pabst Thomas, Maertens Johan, Beverloo H. Berna, van Marwijk Kooy Marinus, Wijermans Pierre W., Biemond Bart J., Vellenga Edo, Verdonck Leo F., Ossenkoppele Gert J., Löwenberg Bob, Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories, 10.1200/jco.2011.39.6499
  25. Schlenk Richard F., Döhner Konstanze, Mack Silja, Stoppel Michael, Király Franz, Götze Katharina, Hartmann Frank, Horst Heinz A., Koller Elisabeth, Petzer Andreas, Grimminger Wolfgang, Kobbe Guido, Glasmacher Axel, Salwender Hans, Kirchen Heinz, Haase Detlef, Kremers Stephan, Matzdorff Axel, Benner Axel, Döhner Hartmut, Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A, 10.1200/jco.2010.28.6856
  26. Schlenk R. F., Taskesen E., van Norden Y., Krauter J., Ganser A., Bullinger L., Gaidzik V. I., Paschka P., Corbacioglu A., Gohring G., Kundgen A., Held G., Gotze K., Vellenga E., Kuball J., Schanz U., Passweg J., Pabst T., Maertens J., Ossenkoppele G. J., Delwel R., Dohner H., Cornelissen J. J., Dohner K., Lowenberg B., The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA, 10.1182/blood-2013-05-503847
  27. Anderson JR, J Clin Oncol, 1, 710 (1983)
  28. Löwenberg Bob, Pabst Thomas, Vellenga Edo, van Putten Wim, Schouten Harry C., Graux Carlos, Ferrant Augustin, Sonneveld Pieter, Biemond Bart J., Gratwohl Alois, de Greef Georgine E., Verdonck Leo F., Schaafsma Martijn R., Gregor Michael, Theobald Matthias, Schanz Urs, Maertens Johan, Ossenkoppele Gert J., Cytarabine Dose for Acute Myeloid Leukemia, 10.1056/nejmoa1010222
  29. Cornelissen Jan J, van der Holt Bronno, Petersen Eefke J, Vindelov Lars, Russel Charlotte A, Höglund Martin, Maertens Johan, Schouten Harry C, Braakman Eric, Steijaert Monique M.C, Zijlmans Mark J.M, Slaper-Cortenbach Ineke, Boogaerts Marc A, Löwenberg Bob, Verdonck Leo F, A randomized multicenter comparison of CD34+-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies, 10.1016/s0301-472x(03)00195-4
  30. Mantel Nathan, Byar David P., Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data, 10.2307/2285503
  31. GRAMBSCH PATRICIA M., THERNEAU TERRY M., Proportional hazards tests and diagnostics based on weighted residuals, 10.1093/biomet/81.3.515
  32. Jourdan E., Boissel N., Chevret S., Delabesse E., Renneville A., Cornillet P., Blanchet O., Cayuela J.-M., Recher C., Raffoux E., Delaunay J., Pigneux A., Bulabois C.-E., Berthon C., Pautas C., Vey N., Lioure B., Thomas X., Luquet I., Terre C., Guardiola P., Bene M. C., Preudhomme C., Ifrah N., Dombret H., , Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, 10.1182/blood-2012-10-462879
  33. Breems Dimitri A., Van Putten Wim L.J., Huijgens Peter C., Ossenkoppele Gert J., Verhoef Gregor E.G., Verdonck Leo F., Vellenga Edo, De Greef Georgine E., Jacky Emanuel, Van der Lelie Johannes, Boogaerts Marc A., Löwenberg Bob, Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse, 10.1200/jco.2005.06.027
  34. Maurillo Luca, Buccisano Francesco, Del Principe Maria Ilaria, Del Poeta Giovanni, Spagnoli Alessandra, Panetta Paola, Ammatuna Emanuele, Neri Benedetta, Ottaviani Licia, Sarlo Chiara, Venditti Daniela, Quaresima Micol, Cerretti Raffaella, Rizzo Manuela, de Fabritiis Paolo, Lo Coco Francesco, Arcese William, Amadori Sergio, Venditti Adriano, Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia, 10.1200/jco.2007.15.9814
  35. Terwijn Monique, van Putten Wim L.J., Kelder Angèle, van der Velden Vincent H.J., Brooimans Rik A., Pabst Thomas, Maertens Johan, Boeckx Nancy, de Greef Georgine E., Valk Peter J.M., Preijers Frank W.M.B., Huijgens Peter C., Dräger Angelika M., Schanz Urs, Jongen-Lavrecic Mojca, Biemond Bart J., Passweg Jakob R., van Gelder Michel, Wijermans Pierre, Graux Carlos, Bargetzi Mario, Legdeur Marie-Cecile, Kuball Jurgen, de Weerdt Okke, Chalandon Yves, Hess Urs, Verdonck Leo F., Gratama Jan W., Oussoren Yvonne J.M., Scholten Willemijn J., Slomp Jennita, Snel Alexander N., Vekemans Marie-Christiane, Löwenberg Bob, Ossenkoppele Gert J., Schuurhuis Gerrit J., High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study, 10.1200/jco.2012.45.9628
  36. Walter Roland B., Gooley Ted A., Wood Brent L., Milano Filippo, Fang Min, Sorror Mohamed L., Estey Elihu H., Salter Alexander I., Lansverk Emily, Chien Jason W., Gopal Ajay K., Appelbaum Frederick R., Pagel John M., Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia, 10.1200/jco.2010.31.8121
  37. Walter R. B., Buckley S. A., Pagel J. M., Wood B. L., Storer B. E., Sandmaier B. M., Fang M., Gyurkocza B., Delaney C., Radich J. P., Estey E. H., Appelbaum F. R., Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission, 10.1182/blood-2013-06-506725
  38. Stelljes Matthias, Krug Utz, Beelen Dietrich W., Braess Jan, Sauerland Maria C., Heinecke Achim, Ligges Sandra, Sauer Tim, Tschanter Petra, Thoennissen Gabriela B., Berning Björna, Kolb Hans J., Reichle Albrecht, Holler Ernst, Schwerdtfeger Rainer, Arnold Renate, Scheid Christoph, Müller-Tidow Carsten, Woermann Bernhard J., Hiddemann Wolfgang, Berdel Wolfgang E., Büchner Thomas, Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis, 10.1200/jco.2013.50.5768
  39. Simon Richard, Makuch Robert W., A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias, 10.1002/sim.4780030106
  40. Breems Dimitri A., Boogaerts Marc A., Dekker Adriaan W., Van Putten Wim L. J., Sonneveld Pieter, Huijgens Peter C., Van der Lelie Johannes, Vellenga Edo, Gratwohl Alois, Verhoef Gregor E. G., Verdonck Leo F., Löwenberg Bob, Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial, 10.1111/j.1365-2141.2004.05282.x
  41. Burnett Alan K, Goldstone Anthony H, Stevens Richard MF, Hann Ian M, Rees John KH, Gray Richard G, Wheatley Keith, Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial, 10.1016/s0140-6736(97)09214-3
  42. Burnett Alan K., Hills Robert K., Milligan Donald W., Goldstone Anthony H., Prentice Archibald G., McMullin Mary-Frances, Duncombe Andrew, Gibson Brenda, Wheatley Keith, Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial, 10.1200/jco.2009.22.9088
  43. Ringdén Olle, Labopin Myriam, Ehninger Gerhard, Niederwieser Dietger, Olsson Richard, Basara Nadezda, Finke Juergen, Schwerdtfeger Rainer, Eder Matthias, Bunjes Donald, Gorin Norbert-Claude, Mohty Mohamad, Rocha Vanderson, Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia, 10.1200/jco.2008.20.9692
  44. Aoudjhane M, Labopin M, Gorin N C, Shimoni A, Ruutu T, Kolb H-J, Frassoni F, Boiron J M, Yin J L, Finke J, Shouten H, Blaise D, Falda M, Fauser A A, Esteve J, Polge E, Slavin S, Niederwieser D, Nagler A, Rocha V, Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT), 10.1038/sj.leu.2403967
  45. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A, Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity, 10.1038/sj.leu.2404037
  46. Flynn Catherine M., Hirsch Betsy, DeFor Todd, Barker Juliet N., Miller Jeffrey S., Wagner John E., Blazar Bruce R., Burns Linda J., MacMillan Margaret L., Arora Mukta, Weisdorf Daniel, Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis, 10.1002/ajh.20989
  47. Alyea Edwin P., Kim Haesook T., Ho Vincent, Cutler Corey, DeAngelo Daniel J., Stone Richard, Ritz Jerome, Antin Joseph H., Soiffer Robert J., Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome, 10.1016/j.bbmt.2006.06.003
  48. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne P A, Hamladji R-M, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M, Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT, 10.1038/bmt.2012.236
  49. Luger S M, Ringdén O, Zhang M-J, Pérez W S, Bishop M R, Bornhauser M, Bredeson C N, Cairo M S, Copelan E A, Gale R P, Giralt S A, Gulbas Z, Gupta V, Hale G A, Lazarus H M, Lewis V A, Lill M C, McCarthy P L, Weisdorf D J, Pulsipher M A, Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS, 10.1038/bmt.2011.69
  50. Bornhäuser Martin, Kienast Joachim, Trenschel Rudolf, Burchert Andreas, Hegenbart Ute, Stadler Michael, Baurmann Herrad, Schäfer-Eckart Kerstin, Holler Ernst, Kröger Nicolaus, Schmid Christoph, Einsele Herrmann, Kiehl Michael G, Hiddemann Wolfgang, Schwerdtfeger Rainer, Buchholz Stefanie, Dreger Peter, Neubauer Andreas, Berdel Wolfgang E, Ehninger Gerhard, Beelen Dietrich W, Schetelig Johannes, Stelljes Matthias, Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial, 10.1016/s1470-2045(12)70349-2
  51. Weiden Paul L., Flournoy Nancy, Thomas E. Donnall, Prentice Ross, Fefer Alexander, Buckner C. Dean, Storb Rainer, Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts, 10.1056/nejm197905103001902
  52. Rowe Jacob M., Graft-versus-disease effect following allogeneic transplantation for acute leukaemia, 10.1016/j.beha.2008.07.002
  53. Gail M. H., Byar D. P., Variance Calculations for Direct Adjusted Survival Curves, with Applications to Testing for No Treatment Effect, 10.1002/bimj.4710280508
Bibliographic reference Cornelissen, J J ; Versluis, J ; Passweg, J R ; van Putten, W L J ; Manz, M G ; et. al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. In: Leukemia, Vol. 29, no. 5, p. 1041-1050 (2015)
Permanent URL http://hdl.handle.net/2078.1/155247